As The Medicines Co. prepares to launch a string of newly approved products in 2015, the company is putting the commercial team in place to target the top hospitals in the U.S. across the product groups, CEO Clive Meanwell said during the company’s first quarter sales and earnings call May. 5.
The Medicines Co. Sets The (Commercial) Stage For New Launches
CEO Clive Meanwell detailed plans to deploy a 400-person commercial group in the U.S. to target 1,100 leading hospitals in the U.S.
More from Archive
More from Pink Sheet
• By
The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.
• By
An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.
• By
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include four new products, one of which is Tivdak, Pfizer/Genmab’s treatment for previously treated recurrent or metastatic cervical cancer.